Literature DB >> 17665982

MicroRNAs as therapeutic targets in human diseases.

Kandiah Jeyaseelan1, Wishva B Herath, Arunmozhiarasi Armugam.   

Abstract

MicroRNAs (miRNAs) are important endogenous regulators of gene expression. The specific regulation at both the transcription and the translation level (inhibition or mRNA degradation) opens an avenue to use these small RNA molecules as potential targets for the development of novel drugs as well as for the diagnosis of several human diseases. Important information about the role of a miRNA in disease can be deduced by mimicking or inhibiting its activity and examining its impact on the phenotype/behaviour of the cell or organism. Modulating the activity of a miRNA is expected to lead to improvement in disease symptoms and this implies that the target miRNA plays an important role in the disease. It is also now possible to develop miRNA-based therapeutic products that can either increase or decrease the levels of proteins in pathophysiological conditions such as cancer, cardiovascular diseases, viral diseases, metabolic disorders and programmed cell death. The commercial potential of miRNA and related drugs is expected to exponentially increase within the next few years, yet there are several areas in miRNA biology and delivery that need to be extensively investigated.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17665982     DOI: 10.1517/14728222.11.8.1119

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  25 in total

1.  miR-181 targets multiple Bcl-2 family members and influences apoptosis and mitochondrial function in astrocytes.

Authors:  Yi-Bing Ouyang; Yu Lu; Sibiao Yue; Rona G Giffard
Journal:  Mitochondrion       Date:  2011-09-17       Impact factor: 4.160

Review 2.  Angiogenesis-regulating microRNAs and Ischemic Stroke.

Authors:  Ke-Jie Yin; Milton Hamblin; Y Eugene Chen
Journal:  Curr Vasc Pharmacol       Date:  2015       Impact factor: 2.719

3.  MicroRNAs: a light into the "black box" of neuropediatric diseases?

Authors:  Ahmed Omran; Dalia Elimam; Sherien Shalaby; Jing Peng; Fei Yin
Journal:  Neuromolecular Med       Date:  2012-07-19       Impact factor: 3.843

Review 4.  The transcriptome of cerebral ischemia.

Authors:  Reyna L VanGilder; Jason D Huber; Charles L Rosen; Taura L Barr
Journal:  Brain Res Bull       Date:  2012-02-21       Impact factor: 4.077

5.  miR-181 regulates GRP78 and influences outcome from cerebral ischemia in vitro and in vivo.

Authors:  Yi-Bing Ouyang; Yu Lu; Sibiao Yue; Li-Jun Xu; Xiao-Xing Xiong; Robin E White; Xiaoyun Sun; Rona G Giffard
Journal:  Neurobiol Dis       Date:  2011-09-24       Impact factor: 5.996

6.  MicroRNAs in CNS injury: potential roles and therapeutic implications.

Authors:  Sindhu K Madathil; Peter T Nelson; Kathryn E Saatman; Bernard R Wilfred
Journal:  Bioessays       Date:  2011-01       Impact factor: 4.345

7.  Structure-activity relationships through sequencing (StARTS) defines optimal and suboptimal RNA motif targets for small molecules.

Authors:  Sai Pradeep Velagapudi; Steven J Seedhouse; Matthew D Disney
Journal:  Angew Chem Int Ed Engl       Date:  2010-05-17       Impact factor: 15.336

8.  miR-155 and miR-31 are differentially expressed in breast cancer patients and are correlated with the estrogen receptor and progesterone receptor status.

Authors:  Zhenduo Lu; Yuping Ye; Dechuang Jiao; Jianhua Qiao; Shude Cui; Zhenzhen Liu
Journal:  Oncol Lett       Date:  2012-08-03       Impact factor: 2.967

9.  miR-497 regulates neuronal death in mouse brain after transient focal cerebral ischemia.

Authors:  Ke-Jie Yin; Zhen Deng; Huarong Huang; Milton Hamblin; Changqing Xie; Jifeng Zhang; Y Eugene Chen
Journal:  Neurobiol Dis       Date:  2010-01-04       Impact factor: 5.996

Review 10.  Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies.

Authors:  Robert C Smallridge; Laura A Marlow; John A Copland
Journal:  Endocr Relat Cancer       Date:  2008-11-05       Impact factor: 5.678

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.